查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015018

抗藥性金黃色葡萄球菌（MRSA）治療市場：依給藥途徑、病患群體、藥物類別及通路分類－2026-2032年全球市場預測

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Administration Route, Patient Type, Drug Class, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗藥性金黃色葡萄球菌(MRSA) 治療市場價值將達到 23.3 億美元，到 2026 年將成長至 24.7 億美元，到 2032 年將達到 34.4 億美元，複合年成長率為 5.70%。

主要市場統計數據
基準年 2025 23.3億美元
預計年份：2026年 24.7億美元
預測年份 2032 34.4億美元
複合年成長率 (%) 5.70%

全面概述了影響現代醫療保健環境中抗藥性金黃色葡萄球菌(MRSA) 治療的臨床、監管和醫療保健系統趨勢。

抗藥性金黃色葡萄球菌（MRSA）因其在任何醫療環境中都可能引起嚴重感染疾病，且具有持續適應治療壓力的能力，仍是一個主要的臨床問題。本執行摘要闡述了多方面的見解，這些見解正在影響著現代臨床管理、藥物研發和醫療系統應對措施。此外，它還揭示了病原體生物學特性的演變、醫療服務模式的改變以及監管力度的加強如何影響製藥公司、醫院和公共衛生相關人員的工作重點。

快速診斷、新興抗生素類別、不斷發展的監管途徑以及管理整合如何重塑針對抗藥性金黃色葡萄球菌的治療方法。

由於分子診斷技術的進步、新型抗生素的出現以及適應性藥物使用政策的調整，抗藥性金黃色葡萄球菌（MRSA）的治療格局正在改變。快速照護現場和近患者診斷技術使得早期標靶治療成為可能，從而減少了經驗性頻譜抗生素的使用，進而影響了處方模式和後續的抗藥性動態。同時，新型藥物的成熟和製劑的改進也豐富了可供選擇的治療方案，使臨床醫生能夠在複雜的患者群體中平衡療效和安全性。

2025 年關稅調整對美國基本抗菌療法的供應鏈策略、採購慣例和取得考量的累積影響。

對於依賴跨境分銷活性藥物成分和成品運輸的製造商、經銷商和醫療保健系統而言，貿易政策和關稅調整至關重要。 2025年實施的關稅調整影響了整個價值鏈的採購成本、供應鏈路線和合約談判，迫使各組織重新評估其籌資策略和庫存緩衝。對於在海外生產專用抗菌劑及其前驅產品的公司而言，這些累積的貿易成本進一步迫使它們最佳化製造地，並盡可能探索近岸外包方案。

透過對給藥途徑、患者環境、藥物類別亞型和分銷管道進行詳細的細分分析，揭示了臨床定位和管道特定影響。

細分市場分析揭示了在給藥途徑、患者環境、藥物分類（用於識別特定藥物）以及分銷管道結構等方面，對臨床應用、商業策略和分銷規劃至關重要的差異。依給藥途徑分析，可以區分靜脈注射和口服給藥，並揭示其對醫院急性期治療管理和門診持續治療的影響。這種差異會影響藥物選擇決策、護理和藥房工作流程以及門診靜脈抗生素治療方案的設計。

影響美洲、歐洲、中東和非洲以及亞太地區治療方法引進、監管途徑、採購模式和供應韌性的區域趨勢。

區域趨勢持續以多元且相互關聯的方式影響臨床應用、監管預期和供應連續性。在美洲，醫療保健系統強調快速實施符合抗菌藥物管理原則的方案，加大對門診輸液服務的投入，以及由支付方主導的藥品清單管理，優先選擇那些安全性和運作效益顯著的治療方法。此外，區域監管環境和報銷途徑也有助於產生嚴格的上市後監測和真實世界數據（REW），從而支持擴大適應症和指南採納。

主要企業如何平衡生命週期管理、新產品開發、供應鏈韌性和市場進入策略，以對抗抗藥性金黃色葡萄球菌？

每家公司的策略都反映了其在維護核心產品系列與追求差異化創新之間的平衡，以應對抗藥性感染疾病、安全問題以及門診給藥的需求。領先的製藥研發公司正致力於最佳化現有藥物的生命週期，同時投資下一代化學技術、替代製劑和臨床項目，以應對難治性感染疾病和合併症患者群體。這些投資通常伴隨著旨在加快研發進度和擴大地域覆蓋範圍的策略聯盟和授權協議。

為製藥公司、支付者和醫療保健提供者提供切實可行的策略建議，以協調診斷、管理、生產和證據生成，從而確保治療的韌性。

產業領導者應優先將以診斷主導的治療路徑、藥物管理協調以及供應鏈冗餘納入策略規劃，以確保患者能夠獲得治療並達到臨床療效。與診斷設備供應商和醫療系統建立更緊密的合作關係，將有助於合理用藥，減少不必要的頻譜抗生素使用。同時，與支付方和醫院系統夥伴關係，可以協調獎勵，促進安全有效的治療方法，從而降低後續成本和不良反應。此外，分散製造地並考慮建立區域生產中心，將有助於減輕貿易和關稅中斷的影響，並維持關鍵藥物供應的連續性。

一種高度透明的多來源調查方法，結合了臨床文獻、相關人員訪談、供應鏈評估和使用真實世界資料的檢驗。

本報告的調查方法結合了同行評審的臨床文獻、監管文件和公共衛生監測資料庫，並輔以對臨床醫生、藥劑師、支付方和行業物流的結構化訪談。在整合證據時，我們優先考慮高品質的臨床試驗數據、安全性報告和指南說明，以確保臨床準確性；同時，我們也利用第一線相關人員的定性見解，為實施、後勤和病患管理等方面的實際考慮提供參考。在適當情況下，我們還評估了真實世界數據（REW）來源，以將試驗結果與常規臨床實踐相結合。

總結如何將治療創新、合理用藥和職業適應力結合起來，以維持對抗抗藥性金黃色葡萄球菌的臨床療效。

總之，抗藥性金黃色葡萄球菌（MRSA）的治療前景正受到診斷技術進步、標靶治療、監管調整以及醫療服務模式演變等多重因素的共同影響。這些因素為改善患者預後創造了機遇，例如透過更精準的處方和更安全、更方便的製劑以及更可靠的實證醫學證據實現商業性差異化。然而，這些因素也對供應鏈的靈活性、醫保報銷機制的完善以及與抗菌藥物管理計畫的整合提出了新的要求，以確保永續使用和持續的臨床療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗藥性金黃色葡萄球菌（MRSA）治療藥物市場（依給藥途徑分類）

  • 靜脈
  • 口服

第9章：依病患類型分類的抗藥性金黃色葡萄球菌(MRSA) 治療市場

  • 住院病人
  • 門診病人

第10章：抗藥性金黃色葡萄球菌（MRSA）治療市場：依藥物類別分類

  • 頭孢菌素
    • 對苯二甲啉
  • 醣肽
    • Teicoplanin
    • 萬古黴素
  • 脂肽
    • Daptomycin
  • Oxazolidinone系列
    • Linezolid
    • 替吉唑胺
  • 四環黴素
    • 埃拉巴西庫林
    • 奇格細胞週期蛋白

第11章：抗藥性金黃色葡萄球菌（MRSA）治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：抗藥性金黃色葡萄球菌（MRSA）治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：抗藥性金黃色葡萄球菌（MRSA）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：抗藥性金黃色葡萄球菌（MRSA）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國抗藥性金黃色葡萄球菌（MRSA）治療市場

第16章：中國抗藥性金黃色葡萄球菌（MRSA）治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Armata Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bausch Health Companies Inc.
  • Cardinal Health, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Innovation Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries ltd
Product Code: MRR-0363DFE0369A

The Methicillin-Resistant Staphylococcus Aureus Drugs Market was valued at USD 2.33 billion in 2025 and is projected to grow to USD 2.47 billion in 2026, with a CAGR of 5.70%, reaching USD 3.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.33 billion
Estimated Year [2026] USD 2.47 billion
Forecast Year [2032] USD 3.44 billion
CAGR (%) 5.70%

A comprehensive orientation to the clinical, regulatory, and health system dynamics shaping treatments for methicillin-resistant Staphylococcus aureus in modern care environments

Methicillin-resistant Staphylococcus aureus remains a focal point of clinical concern due to its capacity to cause severe infections across care settings and its persistent ability to adapt to therapeutic pressures. This executive summary introduces the multidimensional considerations that inform contemporary clinical management, drug development, and health system responses. It highlights how evolving pathogen biology, changing care delivery models, and intensified regulatory scrutiny converge to shape priorities across pharmaceutical, hospital, and public health stakeholders.

The introduction frames the conversation around therapeutic efficacy, safety trade-offs, and the operational realities of delivering care to both acute inpatients and ambulatory populations. It underscores the need for coordinated stewardship, faster diagnostic pathways, and integrated supply chain resilience, while also recognizing the interplay between antimicrobial innovation and the economics of drug development. By setting this context, the report primes readers to understand not only the clinical imperatives but also the systemic levers that will determine adoption, guideline incorporation, and the practical reach of novel and existing treatments.

How rapid diagnostics, emerging antibiotic classes, evolving regulatory pathways, and stewardship integration are reshaping therapeutic approaches to resistant Staphylococcus aureus

The therapeutic landscape for methicillin-resistant Staphylococcus aureus is undergoing transformative shifts driven by advances in molecular diagnostics, novel antibiotic classes, and adaptive stewardship policies. Rapid point-of-care and near-patient diagnostic technologies are reducing empirical broad-spectrum exposure by enabling earlier targeted therapy, which in turn influences prescribing patterns and downstream resistance dynamics. Simultaneously, the maturation of newer drug classes and reformulated agents has diversified available options, allowing clinicians to balance potency with safety profiles in complex patient populations.

Concurrently, regulatory frameworks are evolving to expedite access to high-need antimicrobials while maintaining rigorous safety standards, and health systems are increasingly embedding antimicrobial stewardship within clinical pathways and quality metrics. These combined shifts are prompting payers and providers to reassess formulary placement, outpatient intravenous therapy pathways, and hospital-at-home models that can alter utilization patterns. As a result, stakeholders must adapt commercial strategies, clinical education, and supply logistics to meet demand that is more nuanced, settings-driven, and sensitive to diagnostic-supported prescribing.

The cumulative effects of 2025 tariff adjustments on supply chain strategies, procurement practices, and access considerations for essential antimicrobial therapies in the United States

Trade policy and tariff adjustments have become meaningful considerations for manufacturers, distributors, and health systems that rely on cross-border active pharmaceutical ingredient flows and finished product shipments. Tariff changes implemented in 2025 impacted procurement costs, supply chain routing, and contractual negotiations across the value chain, prompting organizations to reassess sourcing strategies and inventory buffers. For companies manufacturing specialized antimicrobials or their precursors offshore, these cumulative trade costs have introduced additional pressure to optimize manufacturing footprints and to explore nearshoring options where feasible.

In response, manufacturers have been recalibrating supplier agreements, increasing transparency around landed costs, and accelerating investments in regional manufacturing capabilities to mitigate exposure to tariff volatility. Hospitals and pharmacies have adjusted procurement timelines and contingency plans to preserve continuity of care, prioritizing critical antimicrobials in stock rotation and emergency purchasing protocols. Importantly, the tariff environment has sharpened focus on total cost of ownership rather than unit price alone, encouraging collaborative contracting models between manufacturers and large healthcare purchasers to distribute risk and ensure reliable access to essential therapies.

Detailed segmentation analysis across administration routes, patient settings, drug class subtypes and distribution channels illuminating clinical positioning and channel-specific implications

Segmentation analysis reveals important distinctions that inform clinical use, commercial strategy, and distribution planning across administration route, patient setting, drug class taxonomy with specific agents identified, and channel architecture. Examination by administration route differentiates between intravenous and oral forms, with implications for hospital-based acute management and outpatient continuity of care; this dichotomy affects formulary decisions, nursing and pharmacy workflows, and the design of outpatient parenteral antimicrobial therapy programs.

Patient-type segmentation contrasts inpatient and outpatient populations, underscoring divergent therapeutic objectives: rapid, life-saving intervention in acute settings versus treatment adherence, monitoring, and safety considerations in ambulatory care. The drug class segmentation delineates cephalosporins, glycopeptides, lipopeptides, oxazolidinones, and tetracyclines, and further identifies key agents such as ceftaroline within cephalosporins; teicoplanin and vancomycin within glycopeptides; daptomycin within lipopeptides; linezolid and tedizolid within oxazolidinones; and eravacycline and tigecycline within tetracyclines. These class- and agent-level distinctions illuminate clinical positioning, resistance profiles, adverse event monitoring requirements, and potential opportunities for label expansion or life-cycle management.

Distribution channel segmentation differentiates hospital pharmacy, online pharmacy, and retail pharmacy pathways, highlighting how channel choice influences cold chain logistics, dispensing controls, reimbursement mechanisms, and patient access models. Taken together, these segmentation lenses provide a matrix for mapping clinical indications to commercial pathways and for tailoring educational, reimbursement, and supply strategies across diverse care environments.

Regional dynamics influencing therapeutic adoption, regulatory pathways, procurement models, and supply resilience across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape clinical adoption, regulatory expectations, and supply continuity in distinct but interrelated ways. In the Americas, health systems emphasize rapid adoption of stewardship-aligned protocols, investment in outpatient infusion services, and payer-driven formulary management that privileges therapies demonstrating clear safety and operational advantages. This region's regulatory landscape and reimbursement pathways also incentivize rigorous post-market surveillance and real-world evidence generation to support label expansion and guideline inclusion.

Europe, Middle East & Africa encompasses heterogeneous regulatory regimes and diverse procurement models, where centralized tendering in some markets contrasts with fragmented, decentralized purchasing in others. Stakeholders here must navigate varying approval timelines, differential access to novel agents, and the operational complexity of distributing specialized antimicrobials across countries with disparate infrastructure. Regional collaboration on antimicrobial resistance surveillance and stewardship initiatives is increasingly important to harmonize clinical practice and to support cross-border public health responses.

Asia-Pacific presents a mix of high-volume treatment settings, rapidly modernizing healthcare infrastructure, and expanding outpatient care delivery. Market participants operating in this region encounter variable regulatory environments and accelerating adoption of diagnostic-led prescribing in urban centers, while rural healthcare delivery continues to rely on established therapeutic regimens. Regional manufacturing capacity expansion and supply chain diversification are key themes, driven by both demand growth and policy efforts to strengthen pharmaceutical self-sufficiency.

How leading companies are balancing lifecycle management, novel development, supply chain resilience, and market access strategies to address resistant Staphylococcus aureus

Company strategies reveal a balance between preserving core product portfolios and pursuing differentiated innovations to address resistant infections, safety concerns, and outpatient administration imperatives. Leading pharmaceutical developers are allocating resources to life-cycle optimization for established agents while concurrently investing in next-generation chemotypes, alternative formulations, and clinical programs that address difficult-to-treat infections and patient populations with comorbidities. These investments are frequently accompanied by strategic partnerships and licensing arrangements aimed at accelerating development timelines and expanding geographic reach.

Commercial and manufacturing plays are equally important: firms are enhancing supply chain transparency, securing multiple sourcing pathways for critical inputs, and exploring local manufacturing partnerships to reduce regional exposure to trade disruptions. On the market access front, companies are focusing on health economic evidence generation, engagement with stewardship programs, and tailored value communication that aligns with payer priorities. Strategic differentiation also manifests through educational initiatives for clinicians and pharmacists, digital support tools for outpatient therapy adherence, and post-market surveillance collaborations that build clinician confidence and support guideline consideration.

Actionable strategic recommendations for manufacturers, payers, and providers to align diagnostics, stewardship, manufacturing, and evidence generation for therapeutic resilience

Industry leaders should prioritize integrating diagnostic-driven pathways, stewardship alignment, and supply chain redundancy into strategic planning to safeguard therapeutic access and clinical impact. Establishing closer collaboration with diagnostic vendors and health systems can accelerate appropriate prescribing and reduce unnecessary broad-spectrum use, while partnerships with payers and hospital systems can align incentives around effective, safe therapies that reduce downstream costs and adverse outcomes. Simultaneously, diversifying manufacturing sources and considering regional production hubs can mitigate exposure to trade and tariff disruptions and preserve continuity of supply for critical agents.

From a development standpoint, focusing on tolerability profiles, oral bioavailability where feasible, and formulations that support outpatient administration will expand clinical utility and ease integration into alternate care settings. Companies should also invest in pragmatic real-world evidence programs to demonstrate value in routine care and to facilitate adaptive reimbursement pathways. Finally, proactive engagement with stewardship programs, regulators, and clinical societies can help shape guideline inclusion and ensure that new and existing therapies are deployed in ways that maximize patient benefit while minimizing resistance pressure.

Transparent multi-source methodology combining clinical literature synthesis, stakeholder interviews, supply chain assessment, and real-world evidence triangulation

The research methodology underpinning this report combines a synthesis of peer-reviewed clinical literature, regulatory documentation, public health surveillance databases, and structured interviews with clinicians, pharmacists, payers, and industry executives. Evidence synthesis prioritized high-quality clinical trial data, safety reporting, and guideline statements to ensure clinical accuracy, while qualitative insights from frontline stakeholders informed practical considerations around adoption, logistics, and patient management. Where appropriate, real-world evidence sources were evaluated to contextualize trial findings in routine practice.

Analytical approaches included cross-sectional assessment of therapeutic positioning across administration route and patient setting, agent-level clinical profile mapping, and channel analysis focused on distribution, dispensing, and reimbursement mechanics. Supply chain and policy impacts were assessed through scenario analysis and stakeholder consultations to capture operational responses to tariffs and procurement shifts. Throughout, the methodology emphasized transparency of sources, triangulation of findings across independent inputs, and clear documentation of assumptions that guided interpretation and conclusions.

Concluding synthesis on how therapeutic innovation, stewardship integration, and operational resilience must converge to sustain clinical effectiveness against resistant Staphylococcus aureus

In conclusion, the landscape for methicillin-resistant Staphylococcus aureus therapies is being reshaped by concurrent advances in diagnostics, targeted therapeutics, regulatory adaptation, and changing care delivery models. These forces create opportunities for improved patient outcomes through more precise prescribing and for commercial differentiation through safer, more convenient formulations and robust evidence generation. However, they also impose new requirements for supply chain agility, reimbursement engagement, and integration with stewardship programs to ensure sustainable use and continued clinical effectiveness.

Decision-makers across manufacturers, health systems, and payers must therefore adopt a holistic approach that links therapeutic innovation to practical deployment considerations, including channel strategy, inpatient-outpatient transitions, and regional regulatory variability. By aligning clinical development, market access planning, and operational resilience, stakeholders can better navigate the evolving environment and deliver therapies that meet clinical needs while mitigating the risks associated with resistance and supply disruption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Administration Route

  • 8.1. Intravenous
  • 8.2. Oral

9. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Patient Type

  • 9.1. Inpatient
  • 9.2. Outpatient

10. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class

  • 10.1. Cephalosporins
    • 10.1.1. Ceftaroline
  • 10.2. Glycopeptides
    • 10.2.1. Teicoplanin
    • 10.2.2. Vancomycin
  • 10.3. Lipopeptides
    • 10.3.1. Daptomycin
  • 10.4. Oxazolidinones
    • 10.4.1. Linezolid
    • 10.4.2. Tedizolid
  • 10.5. Tetracyclines
    • 10.5.1. Eravacycline
    • 10.5.2. Tigecycline

11. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Methicillin-Resistant Staphylococcus Aureus Drugs Market

16. China Methicillin-Resistant Staphylococcus Aureus Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Armata Pharmaceuticals, Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Basilea Pharmaceutica Ltd.
  • 17.9. Bausch Health Companies Inc.
  • 17.10. Cardinal Health, Inc.
  • 17.11. Cumberland Pharmaceuticals Inc.
  • 17.12. Innovation Pharmaceuticals Inc.
  • 17.13. Johnson & Johnson Services, Inc.
  • 17.14. Merck & Co., Inc.
  • 17.15. Novartis AG
  • 17.16. Paratek Pharmaceuticals, Inc.
  • 17.17. Pfizer Inc.
  • 17.18. Takeda Pharmaceutical Company Limited
  • 17.19. Teva Pharmaceutical Industries ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 169. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 170. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 172. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 200. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 202. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 209. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 211. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)